B Cell Lymphoma
From the Journals
Adding lymphopenia component ‘improves’ FLIPI
The FLIPI-L could better predict survival and histologic transformation, when compared with the original FLIPI.
Video
Experts break down latest CAR T-cell advances in lymphoma
ORLANDO – An expert panel of physicians discusses the latest research on CAR T-cell therapy in lymphoma, presented at the 2019 annual meeting of...
Conference Coverage
REGN1979 shows good activity in pretreated aggressive B-NHL
...
Guidelines
NCCN guidelines highlight ‘complicated’ treatment for pediatric lymphomas
The guidelines include recommendations for managing pediatric Burkitt lymphoma and diffuse large B-cell lymphoma.
Conference Coverage
CAR T-cell therapy advances in CLL
ORLANDO – The safety and clinical activity of the CD19-directed CAR T-cell agent justifies moving forward with phase 2 investigation, researchers...
Conference Coverage
LOXO-305: Next-gen BTK inhibitor safe and effective in B-cell malignancies
ORLANDO – The antitumor activity of the novel drug was significant among patients with chronic lymphocytic leukemia and mantle cell lymphoma.
Conference Coverage
Survival data reported from largest CAR T trial in B-cell lymphoma
ORLANDO – Progression-free survival results were best among complete responders and patients with primary mediastinal large B-cell lymphoma or...
Conference Coverage
Zanubrutinib achieved high response rate in del(17p) CLL cohort
ORLANDO – The study looked at responses in a cohort of patients with historically poor prognosis and response to chemotherapy.
Conference Coverage
Some MCL patients can safely stop venetoclax-ibrutinib, study suggests
ORLANDO - The study raises the possibility of limited-duration, targeted-agent therapy in relapsed/refractory mantle cell lymphoma.
Conference Coverage
KTE-X19 produces highest response rate in MCL subgroup
ORLANDO – The CAR T-cell therapy produced the highest reported response rate in mantle cell lymphoma patients who have failed treatment with a...
Conference Coverage
An off-the-shelf drug to rival CAR T cells: ‘very exciting’
ORLANDO – Mosunetuzumab is a bispecific antibody that targets both CD3 and CD20. It was tested in a phase 1/1b trial among patients with relapsed/...